







Supplementary material 1


The primary *in-vitro* spotting assay utilized for the initial assessment of the inhibitory effect of compounds identified by the *in-silico* screening strategy. Assays were carried out using RPMI-MOPS with 2% glucose and 2% agar plates with final drug concentration of 50µM, *Candida auris* isolates belonging clade I (AR389), clade II (CBS10913), clade III (AR383), clade IV (AR385), clade V (AR1097), *Candida albicans* (SC5314) and *Candida glabrata* (ATCC2001) were used. Spotting was performed by a robotic arm, following which plates were monitored over time for fungal growth. The following compounds were screened: Carboxin (mw: 235.30), Cladribine (mw: 285.69), Colchicine (mw: 399.43), Dasatinib (mw: 488.01), Enasidenib (mw: 473.38), Fostamatinib (mw: 580.46), Griseofulvin (mw: 352.77), Mupirocin (mw: 500.62), Pemetrexed (mw: 427.41), Pimecrolimus (mw: 810.45), Selinexor (mw: 443.31), Sulfinpyrazone (mw: 404.12), Tavaborole (mw: 151.93), Triclabendazole (mw: 359.65) and additionally AmB 2µg/mL, control RPMI-MOPS and control YPD plates.



7. Griseofulvin

24h


48h



8. Mupirocin

24h


48h



9. Pemetrexed

24h


48h



10. Pimecrolimus

24h


48h



11. Selinexor

24h


48h



12. Sulfinpyrazone

24h


48h



13. Tavaborole


24h

48h




72h

96h




120h



14. Triclabendazole

24h


48h



15. AmB

24h


48h



16. RPMI-MOPS control

24h

48h



17. YPD control

24h

48h

